By
Drug Target Review2025-11-27T08:30:08
A new mRNA therapy that prompts the body to produce bacteria-killing ‘peptibodies’ has shown early success in preclinical models, offering a potential new tool in the fight against antibiotic-resistant pneumonia.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-06-19T08:26:00Z
2026-06-17T09:14:00Z
2025-10-22T14:00:00
Sponsored by Wuxi Biologics
2025-04-02T14:00:00
Sponsored by Eurofins Discovery
2025-05-14T14:30:00
Sponsored by Abzena
2023-03-07T10:55:58
Sponsored by Agilent
2023-07-04T10:05:58
Sponsored by Revvity
2025-05-08T10:38:52
Sponsored by Takara Bio USA
Site powered by Webvision Cloud